摘要:
A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase
摘要:
The present invention provides a compound of formula (I), wherein R?1 and R2¿ are the same or different and are independently H, C¿1?-C6 straight-chain or branched-chain saturated or unsaturated alkyl, aryl, R?6CH¿2-, R6CO-, or R6SO2-, wherein R6 is H, C¿1?-C6 straight-chain or branched-chain saturated or unsaturated alkyl, or aryl; R?3¿ is H, C¿1?-C6 straight-chain or branched-chain saturated alkyl, aryl, an oxime, or an oxime methyl ether; at least one aromatic ring position is optionally substituted with a substituent selected from the group consisting of halo, nitro, amino, hydroxyl, thio, acyl, C1-C6 alkyl, and cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms (including heteroatoms) which atoms, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR?1¿ and ending with the carbon directly attached to the alkyl oxygen of the lactone, which carbons are covalently bonded to either end of linker Z, integrally form a 12-15 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof. The present invention further provides a pharmaceutical composition, and a method of preventing or treating cancer, using at least one compound of the present invention, optionally in conjunction with an additional compound other than a compound of the present invention.
摘要:
The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl, alkenyl or aryl, R3 is H, alkyl, alkenyl or aryl, R?4 and R4-R8¿ are independently R?10, C(O)R10¿ or SO¿2R?10, wherein R10 is H, alkyl, alkenyl or aryl, and R?9 is R9a, C(O)R9a¿ or SO¿2R?9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(=O), OR9b, OC(O)R9b, OSO2R?9b, NHR9b¿, NHC(O)R9b and NHSO¿2R?9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(=O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.
摘要:
The present invention provides new monomeric derivatives of the C-8'-7 linked naphthylisoquinoline alkaloid dioncophylline D. The invention also provides new C-4 substituted monomeric arylisoquinoline alkaloid derivatives. The present invention furthermore provides novel dimeric arylisoquinoline alkaloids comprised of coupled first and second arylisoquinoline monomers, wherein either or both of said monomer(s) is (are) monomeric compound(s) of the present invention. Monomeric and dimeric compounds of the present invention have medically useful properties, such as antimicrobial properties, more specifically such as antimalarial and antiviral properties. Monomeric compounds of the present invention are also useful as building blocks or intermediates for synthesis of novel dimeric arylisoquinoline alkaloids. Monomeric and dimeric compounds of the present invention may be obtained in substantially pure form by total synthesis, partial synthesis, or derivatization from known synthetic or naturally occurring compounds, and by isolation and purification from plants of the Dioncophyllaceae and Ancistrocladaceae families.